Floatz Rating
B60/100
Confidence
Indicative
Sponsor
University of Southern California
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02935361CT.gov Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | — | Active Not Recruiting | — | — | — |
NCT02684162CT.gov Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | — | Completed | — | — | — |
NCT01261312CT.gov SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Myelomonocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Guadecitabine (this asset) | University of Southern California | P2 | B · 60 |
| Pevonedistat | Takeda | P3 | BB |
| Venetoclax | Servier Bio-Innovation LLC | P2/3 | BB |
| Astx727 | Taiho Oncology, Inc. | P3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BB |
| Melphalan | City of Hope Medical Center | P2 | BB |
| Azacitidine | The University of Hong Kong | P3 | BB |
| Idarubicin | Fred Hutchinson Cancer Center | P3 | BB |
| Tacrolimus | City of Hope Medical Center | P2 | BB |
+42 more in the Chronic Myelomonocytic Leukemia cohort
Other indications for Guadecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fallopian Tube Carcinoma | — | P2 | BB · 66 |
| Ovarian Carcinoma | — | P2 | BB · 66 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Guadecitabine in Chronic Myelomonocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/guadecitabine-chronic-myelomonocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →